Immune thrombocytopenic purpura -- let the treatment fit the patient

Article Abstract:

Many people who have immune thrombocytopenic purpura may not need treatment as long as they do not develop serious bleeding. Patients with platelet counts of only 30,000 or more have done very well without treatment. If they have other risk factors for bleeding, they should be treated with high-dose corticosteroid drugs for just a few days to minimize the side effects of these drugs.

Editorial

---

Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone

Article Abstract:

High-dose dexamethasone may be effective in treating immune thrombocytopenic purpura, according to a study of 125 patients who took 40 milligrams of the drug for four days. Unfortunately, half of the patients had a relapse within three to six months. Immune thrombocytopenic purpura is an autoimmune disease caused by the destruction of cells that participate in blood clot formation.

---

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

Article Abstract:

The results from randomized trial conducted to determine thrombopoietin-receptor agonist eltrombopag as an effective treatment among adults with chronic idiopathic thrombocytopenic purpura (ITP) is reported. Eltrombopag was found to increase platelet counts in a dose-dependent manner in patients with relapsed or refractory ITP.

United States, Science & research, Research, Complications and side effects, Platelet activating factor, Thrombopoietin, Clinical report

Similar abstracts:

• Abstracts: Learning from past complaints to improve the care of patients. Are nurse picking up doctors' unwanted tasks?
• Abstracts: Putting agency nursing in the spotlight. Improving support for renal patients. How to ... write a proposal; got a great idea but not sure how to develop it? Writing a proposal can be the first step towards putting your idea into action and improving patient care
• Abstracts: Estrogen plus progestin and the risk of coronary heart disease. Inflammatory markers and the risk of coronary heart disease in men and women
• Abstracts: Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
• Abstracts: Implementation of the Ottawa ankle rules in France: a multicenter randomized controlled trial. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.